Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch
        educational campaign about emerging science in type 2 diabetes

The SGLT disease education campaign provides resources for healthcare
professionals about the role of sodium glucose co-transporters in maintaining
blood sugar balance

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, May 2, 2013

RIDGEFIELD, Conn.and INDIANAPOLIS, May 2, 2013 /PRNewswire/ --Boehringer
Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today
announced the launch of  an educational campaign designed to provide
healthcare professionals (HCPs) with a greater understanding of the role
sodium glucose co-transporters (SGLTs) play in maintaining blood sugar
balance, or glucose homeostasis.^1

The SGLT disease education initiative features the microsite www.SGLT.com and
a short dynamic educational video, Glucose Perspectives, in the form of sketch
animation by the Royal Society for the encouragement of Arts, Manufactures and
Commerce (RSA). Additional learning options will be offered throughout the
year for HCPs to learn more about SGLTs and their role in glucose homeostasis.

A chronic condition, type 2 diabetes mellitus (T2D) is characterized by
persistent high blood sugar levels (hyperglycemia).^2 The inability to
maintain normal blood sugar balance is due either to an inability to respond
properly to the hormone insulin, also known as insulin resistance, or to
inadequate amounts of insulin in the body as a result of impaired beta-cell
function, or a combination of the two.

SGLTs act to ensure glucose entering the kidneys finds its way back into the
bloodstream instead of being passed in the urine.^3 Nearly all of the filtered
glucose is reabsorbed in the kidneys by sodium glucose co-transporters 1 and
2, with SGLT2 accounting for about 90 percent of this re-absorption. ^3

In people with T2D, persistent hyperglycemia can lead to increased
re-absorption of glucose through SGLT2.^1 This means more glucose is being
reabsorbed into the blood in a continuous action, which perpetuates
hyperglycemia and worsens beta-cell function and insulin resistance.

"The contribution of insulin resistance and impaired beta-cell function in the
physiopathology of type 2 diabetes mellitus has been extensively studied,"
said Christophe Arbet-Engels, MD, PhD, vice president, metabolic-clinical
development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
"The contributing role of persistently high glucose levels in the progression
of type 2 diabetes has led to the need for a better understanding of how
glucose is reabsorbed by the kidneys. The Boehringer Ingelheim and Lilly
Diabetes alliance is very pleased to offer healthcare professionals an
educational resource they can use at their convenience to gain greater
knowledge of this process."

About Diabetes
Approximately 25.8 million Americans^4 and an estimated 371 million people
worldwide^5 have type 1 or type 2 diabetes. T2D is the most common type,
accounting for an estimated 90 percent of all diabetes cases.^4 Diabetes is a
chronic condition that occurs when the body either does not properly produce,
or use, the hormone insulin.^2 Diabetes was estimated to cost the U.S. $245
billion in 2012.^6

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an
alliance in the field of diabetes that centers on three pipeline compounds
representing several of the largest treatment classes. This alliance leverages
the companies' strengths as two of the world's leading pharmaceutical
companies, combining Boehringer Ingelheim's solid track record of
research-driven innovation and Lilly's innovative research, experience, and
pioneering history in diabetes. By joining forces, the companies demonstrate
commitment in the care of patients with diabetes and stand together to focus
on patient needs. Find out more about the alliance at
www.boehringer-ingelheim.com or www.lilly.com.

About Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the
largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT)
and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical
companies.Headquartered in Ingelheim, Germany, it operates globally with 140
affiliates and more than 46,000 employees.Since it was founded in 1885, the
family-owned company has been committed to researching, developing,
manufacturing and marketing novel medications of high therapeutic value for
human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim has a demonstrated
commitment to corporate social responsibility.Involvement in social projects,
caring for employees and their families, and providing equal opportunities for
all employees form the foundation of the global operations. Mutual cooperation
and respect, as well as environmental protection and sustainability are
intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about $19.1 billion (14.7
billion euro). R&D expenditure in the business area Prescription Medicines
corresponds to 22.5% of its net sales.

For more information please visitwww.us.boehringer-ingelheim.com

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, IN, Lilly provides answers –
through medicines and information – for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced
the world's first commercial insulin. Today we work to meet the diverse needs
of people with diabetes through research and collaboration, a broad and
growing product portfolio and our continued commitment to providing real
solutions – from medicines to support programs and more – to make lives
better.

For more information, visit www.lillydiabetes.com.

P-LLY
DIA551291PR

CONTACT:
Catherine London
Associate Director, Public Relations
Boehringer Ingelheim Pharmaceuticals, Inc.
Email: usnews@boehringer-ingelheim.com
Phone: (203) 798-4638

Tammy Hull
Communications Manager
Lilly Diabetes
Email: hullta@lilly.com
Phone: (317) 651-9116

1.Hardman TC, Dubrey SW. Diabetes Ther. 2011;2(3):133–145.
2.International Diabetes Federation. IDF Diabetes Atlas, 5th Edition: What
    is Diabetes? http://www.idf.org/diabetesatlas/5e/what-is-diabetes.
    Accessed on: April 29, 2013
3.Abdul-Ghani MA, DeFronzo RA. Endocr Pract. 2008;14(6):782-790.
4.Centers for Disease Control and Prevention. National Diabetes Fact Sheet:
    National Estimates and General Information on Diabetes and Prediabetes in
    the United States, 2011. Atlanta, GA: U.S. Department of Health and Human
    Services, Centers for Disease Control and Prevention, 2011.
5.International Diabetes Federation. IDF Diabetes Atlas Poster. 2012 Update.
    2012 (5th Edition).
6.American Diabetes Association. Diabetes Care. 2013;36(4):1033-1046.



(Logo: http://photos.prnewswire.com/prnh/20110825/DE57898LOGO )

(Logo:http://photos.prnewswire.com/prnh/20031219/LLYLOGO )



SOURCE Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals, Inc.

Website: http://www.lilly.com
 
Press spacebar to pause and continue. Press esc to stop.